IQVIA Holdings Inc. (NYSE:IQV) Position Raised by Handelsbanken Fonder AB

Handelsbanken Fonder AB raised its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 12.3% in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 267,319 shares of the medical research company’s stock after purchasing an additional 29,362 shares during the quarter. Handelsbanken Fonder AB owned about 0.15% of IQVIA worth $63,347,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of IQV. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main raised its position in IQVIA by 339.6% in the fourth quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 2,067,195 shares of the medical research company’s stock worth $478,308,000 after acquiring an additional 1,597,003 shares in the last quarter. 1832 Asset Management L.P. lifted its stake in IQVIA by 472.3% during the second quarter. 1832 Asset Management L.P. now owns 456,335 shares of the medical research company’s stock valued at $96,487,000 after purchasing an additional 376,595 shares during the last quarter. Renaissance Technologies LLC bought a new stake in IQVIA during the second quarter worth approximately $70,610,000. Cadian Capital Management LP acquired a new position in IQVIA in the fourth quarter worth approximately $70,108,000. Finally, Impax Asset Management Group plc increased its holdings in shares of IQVIA by 19.3% in the second quarter. Impax Asset Management Group plc now owns 1,635,201 shares of the medical research company’s stock valued at $344,998,000 after buying an additional 264,555 shares in the last quarter. 89.62% of the stock is currently owned by institutional investors and hedge funds.

IQVIA Stock Performance

IQVIA stock traded up $2.44 during trading hours on Friday, reaching $229.84. 591,239 shares of the company were exchanged, compared to its average volume of 1,077,197. IQVIA Holdings Inc. has a 12 month low of $167.42 and a 12 month high of $261.73. The firm has a market cap of $41.88 billion, a price-to-earnings ratio of 31.40, a PEG ratio of 2.21 and a beta of 1.49. The company has a current ratio of 0.85, a quick ratio of 0.85 and a debt-to-equity ratio of 1.80. The stock has a 50-day moving average of $240.74 and a 200 day moving average of $232.55.

IQVIA (NYSE:IQV) last posted its earnings results on Monday, July 22nd. The medical research company reported $2.64 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.57 by $0.07. The business had revenue of $3.81 billion for the quarter, compared to analyst estimates of $3.79 billion. IQVIA had a net margin of 9.39% and a return on equity of 28.59%. IQVIA’s revenue was up 2.3% compared to the same quarter last year. During the same period last year, the business posted $2.22 EPS. As a group, research analysts anticipate that IQVIA Holdings Inc. will post 10.25 earnings per share for the current year.

Insider Activity at IQVIA

In other news, insider Eric Sherbet sold 1,300 shares of the company’s stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total transaction of $320,229.00. Following the completion of the transaction, the insider now directly owns 19,536 shares in the company, valued at $4,812,302.88. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.60% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on IQV shares. Morgan Stanley lifted their target price on IQVIA from $270.00 to $280.00 and gave the stock an “overweight” rating in a report on Tuesday, July 23rd. Barclays boosted their target price on shares of IQVIA from $255.00 to $275.00 and gave the company an “overweight” rating in a research note on Tuesday, July 23rd. Truist Financial raised their target price on IQVIA from $292.00 to $300.00 and gave the stock a “buy” rating in a research report on Tuesday, July 23rd. Argus raised IQVIA to a “strong-buy” rating in a research report on Wednesday, July 31st. Finally, Royal Bank of Canada assumed coverage on IQVIA in a research report on Wednesday, September 4th. They set an “outperform” rating and a $275.00 price objective for the company. Five investment analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $267.00.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.